Market Overview

UPDATE: Stifel Nicolaus Raises PT to $9 on Boston Scientific Corporation Post Analyst Day

Share:
Related BSX
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2
Opinion: Here Are 10 Trends (And 11 Investments) To Watch In 2015
Will Abiomed (ABMD) Outshine Q3 Earnings Estimates? - Analyst Blog (Zacks)

Stifel Nicolaus maintained Boston Scientific Corporation (NYSE: BSX) with a Buy rating and raised the price target from $8.00 to $9.00.

Stifel Nicolaus noted, "We left yesterday's Boston Scientific New York Analyst Day believing our basic thesis on BSX shares is unchanged. If anything, we left with increased conviction that after three years of negative top-line growth, BSX now has in place multiple avenues to re-accelerate sales growth back to mid-single digits by the 2016-2017 time frame. … Also evident throughout the meeting was the strong management team now in place at BSX and their clear and energetic strategic vision for the company. Overall, management laid out what we thought was a well thought-out and realistic plan to improve the growth and profitability prospects of the company."

Boston Scientific Corporation closed at $7.59 on Tuesday.

Latest Ratings for BSX

DateFirmActionFromTo
Jan 2015Leerink SwannUpgradesMarket PerformOutperform
Oct 2014Goldman SachsUpgradesSellNeutral
Oct 2014BenchmarkUpgradesHoldBuy

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings

 

Related Articles (BSX)

Around the Web, We're Loving...

Get Benzinga's Newsletters